359 related articles for article (PubMed ID: 33780665)
1. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
[TBL] [Abstract][Full Text] [Related]
2. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
Thromb Haemost; 2024 Jul; 124(7):676-683. PubMed ID: 38196077
[TBL] [Abstract][Full Text] [Related]
3. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
[TBL] [Abstract][Full Text] [Related]
4. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
5. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
6. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
7. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
10. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
Agnelli G; Muñoz A; Franco L; Mahé I; Brenner B; Connors JM; Gussoni G; Hamulyak EN; Lambert C; Suero MR; Bauersachs R; Torbicki A; Becattini C
Thromb Haemost; 2022 May; 122(5):796-807. PubMed ID: 34530482
[TBL] [Abstract][Full Text] [Related]
11. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Giustozzi M; Connors JM; Ruperez Blanco AB; Szmit S; Falvo N; Cohen AT; Huisman M; Bauersachs R; Dentali F; Becattini C; Agnelli G
J Thromb Haemost; 2021 Nov; 19(11):2751-2759. PubMed ID: 34260816
[TBL] [Abstract][Full Text] [Related]
14. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
[TBL] [Abstract][Full Text] [Related]
15. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
16. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
[TBL] [Abstract][Full Text] [Related]
18. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
Agnelli G; Becattini C; Bauersachs R; Brenner B; Campanini M; Cohen A; Connors JM; Fontanella A; Gussoni G; Huisman MV; Lambert C; Meyer G; Muñoz A; Abreu de Sousa J; Torbicki A; Verso M; Vescovo G;
Thromb Haemost; 2018 Sep; 118(9):1668-1678. PubMed ID: 30103252
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
20. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
Verso M; Agnelli G; Munoz A; Connors JM; Sanchez O; Huisman M; Brenner B; Gussoni G; Cohen AT; Becattini C
Eur J Cancer; 2022 Apr; 165():136-145. PubMed ID: 35235870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
